Sepsis Therapeutics

Sepsis Therapeutics

Global Sepsis Therapeutics Market to Reach $7.1 Billion by 2030
The global market for Sepsis Therapeutics estimated at US$4.2 Billion in the year 2022, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 6.7% over the period 2022-2030. Cephalosporin, one of the segments analyzed in the report, is expected to record 7% CAGR and reach US$3 Billion by the end of the analysis period. Growth in the Glycopeptide Antibiotics segment is estimated at 6.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 8.6% CAGR
The Sepsis Therapeutics market in the U.S. is estimated at US$1.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$776.3 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 45 Featured) -
  • Adrenomed AG
  • AM-Pharma B.V.
  • Asahi Kasei Pharma America
  • Endacea, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GSK Plc
  • InflaRx N.V.
  • Inotrem SA
  • La Jolla Pharmaceutical Company
  • TaiRx, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Sepsis: A Life-Threatening Condition Requiring Urgent Action
Interventions for Managing Sepsis
Treatments that are Commonly Applied for Sepsis
Global Economic Update
Competitive Landscape
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
Global Market Prospects and Outlook
Thriving Global Sepsis Therapeutics Market Oozes Signs of Robust Health
Cephalosporins Hold a Major Share of the Treatment Market
Global Sepsis Therapeutics Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth
Limited Therapeutic Options: A Challenge
Antibiotics and Vasopressors - The Current Standard of Care
Current Categories of Antibacterial Agents for First-line Sepsis Treatment
Current Anti-bacterial Drugs used in Sepsis
Current Antifungals used for Sepsis
GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
Promising Treatment for Sepsis
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Sepsis Propels Market Growth
Aging Population: A Key Growth Driver for Sepsis Therapeutics
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
A Market Characterized by High Unmet Medical Needs
Novel Immune-Specific Modes of Action under Focus
Emphasizing on Endothelial Cell Function
HMGB1- A Potential Target for Future Therapies
Hydrocortisone Displays Potential in Septic Shock Treatment
Reduced Levels of Vitamin C Characterize Sepsis Patients
Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
Anticancer Drugs - Offering Potential Treatment of Sepsis
New Protein to be Effective for Sepsis
Rise in Healthcare Expenditure to Drive Growth
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
AI-Driven Sepsis Screening Approach to Save Lives
Increasing R&D Activity & New Product Launches Spur Market Growth
Purdue Researchers Develop IV Injection for Sepsis
PLK1-mTOR Axis - A Potential Therapeutic for Sepsis
New Nanoparticles - A Revolution in the Development of Clinical Sepsis Therapy
Strong Pipeline and Increased Research Activity Enables Increased Awareness of Disease Pathogenesis
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Sepsis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Glycopeptide Antibiotics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
CANADA
TABLE 29: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: Canada 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
JAPAN
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 35: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Japan 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
CHINA
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 41: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: China Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: China 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
EUROPE
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 47: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
FRANCE
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 56: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: France Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: France 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 59: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
GERMANY
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 62: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Germany 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 65: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
ITALY
TABLE 68: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Italy 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 71: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
UNITED KINGDOM
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 74: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: UK Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: UK 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 77: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
SPAIN
TABLE 80: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Spain 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 83: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Spain 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
RUSSIA
TABLE 86: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Russia 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 89: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Russia 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
AUSTRALIA
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 107: Australia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Australia Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Australia 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 110: Australia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Australia 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
INDIA
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 113: India Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: India Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: India 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 116: India Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: India Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: India 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 119: South Korea Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: South Korea Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: South Korea 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 122: South Korea Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Asia-Pacific Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
LATIN AMERICA
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 131: Latin America Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 134: Latin America Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
MIDDLE EAST
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 137: Middle East Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Middle East Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Middle East 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 140: Middle East Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Middle East Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Middle East 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
AFRICA
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 143: Africa Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Africa Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Africa 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 146: Africa Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Africa Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Africa 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings